Archive

Largest private sector investment in Mecklenburg-Western Pomerania: CHEPLAPHARM makes the megadeal

With an investment of approximately 340 million euros, CHEPLAPHARM Arzneimittel GmbH breaks all private sector records in Mecklenburg-Western...

Read more / pdf

CHEPLAPHARM acquires product rights for ANEXATE® from F. Hofmann-La Roche

Amount of investment in the mid, double-digit million euro range. CHEPLAPHARM creates eight new jobs with this acquisition.

Read more / pdf

CHEPLAPHARM assumes Italian rights for ALDACTONE®

CHEPLAPHARM acquired the product rights for the prescription medication ALDACTONE® in Italy on 09.11.2015, thus boosting its presence within this...

Read more / pdf

CHEPLAPHARM moves into new 2500 square meter office building at Greifswald’s Business Park Ziegelhof

On December 1st CHEPLAPHARM Arzneimittel GmbH moved into a new prestigious office building at Ziegelhof Business Park in the outskirts of the...

Read more

CHEPLAPHARM Arzneimittel GmbH launches 100 million EURO investment program

The pharmaceutical firm CHEPLAPHARM Arzneimittel GmbH has embarked on the biggest ever investment program in the history of the company.

This...

Read more

CHEPLAPHARM continues its rapid growth: 50% sales increase in 2013 compared to the previous year.

Additionally, CHEPLAPHARM acquires Glenwood LLC based in New York, USA.

CHEPLAPHARM continues its rapid growth in 2013. The increase in sales...

Read more

CHEPLAPHARM acquires the rights for VESANOID® and ROHYPNOL® - largest investment since company´s existence.

Products are attained from F. Hoffmann-La Roche and will be exported to more than 90 countries.

Mesekenhagen-based CHEPLAPHARM Arzneimittel GmbH from...

Read more

CHEPLAPHARM attains the rights for HEMINEVRIN®/DISTRANEURIN®

Pharmaceutical product was taken over from AstraZeneca and is distributed in Europe

CHEPLAPHARM, headquartered in Mesekenhagen (Mecklenburg-Western...

Read more